SCHEMBL6535262

SCHEMBL6535262

Cc1cc(C(C)(C)CC(=O)O)ccc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 14/20 0.55
ESR2 Q92731 7/20 0.52
AR P10275 3/20 0.52
VDR P11473 1/20 0.43
CYP2C19 P33261 1/20 0.43
HIF1A Q16665 1/20 0.43
CHEK1 O14757 1/20 0.43
FYN P06241 1/20 0.43
PDGFRB P09619 1/20 0.43
PIM1 P11309 1/20 0.43
FGFR1 P11362 1/20 0.43
FLT1 P17948 1/20 0.43
GRK5 P34947 1/20 0.43
MAP2K2 P36507 1/20 0.43
MAPK8 P45983 1/20 0.43
CDK8 P49336 1/20 0.43
RPS6KA3 P51812 1/20 0.43
PRKX P51817 1/20 0.43
JAK3 P52333 1/20 0.43
LIMK1 P53667 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238030 0.86 ESR1 (0.55) ESR1ESR2ARVDRCYP2C19
SCHEMBL29690460 0.86 ESR1 (0.55) ESR1ESR2ARVDRCYP2C19
SCHEMBL7835864 0.85 CYP2C19 (0.46) ESR1ESR2CYP2C19HIF1ATDP1
SCHEMBL10411503 0.80 CHEK1 (0.49) ESR1ESR2ARCHEK1FYN
SCHEMBL9774879 0.79 ESR1 (0.45) ESR1ESR2CYP2C19HIF1A
SCHEMBL2232385 0.79 ESR1 (0.53) ESR1ESR2ARVDR
SCHEMBL6535890 0.78 SLC13A5 (0.44) VDRCYP2C19
SCHEMBL7823625 0.77 ALDH1A1 (0.46) CYP2C19HIF1ATDP1
SCHEMBL29492899 0.77 ESR1 (0.70) ESR1ESR2ARVDRTP53
SCHEMBL5990790 0.77 ESR1 (0.56) ESR1ESR2ARCYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6689902-B2 REDUCTIVE ALKYLATION AJINOMOTO CO., INC. (JP) 2004-02-10 US claimed
US-20030032842-A1 Novel arylpropyl aldehyde derivatives, processes for producing the same, and methods of using the same AJINOMOTO CO., INC. (JP) 2003-02-13 US claimed
CN-1395551-A Novel arylpropionaldehyde derivatives and production and use of the same AJINOMOTO KK (JP) 2003-02-05 CN claimed
EP-1249442-A1 NOVEL ARYLPROPIONALDEHYDE DERIVATIVES AND PRODUCTION AND USE OF THE SAME Ajinomoto Co., Inc. (JP) 2002-10-16 EP claimed
EP-1249442-A4 NOVEL ARYLPROPIONALDEHYDE DERIVATIVES AND PRODUCTION AND USE OF THE SAME AJINOMOTO KK (JP) 2004-10-13 EP disclosed
US-6689902-B2 REDUCTIVE ALKYLATION AJINOMOTO CO., INC. (JP) 2004-02-10 US disclosed
US-6689902-B2 REDUCTIVE ALKYLATION AJINOMOTO CO., INC. (JP) 2004-02-10 US disclosed
US-20030032842-A1 Novel arylpropyl aldehyde derivatives, processes for producing the same, and methods of using the same AJINOMOTO CO., INC. (JP) 2003-02-13 US disclosed
US-20030032842-A1 Novel arylpropyl aldehyde derivatives, processes for producing the same, and methods of using the same AJINOMOTO CO., INC. (JP) 2003-02-13 US disclosed
CN-1395551-A Novel arylpropionaldehyde derivatives and production and use of the same AJINOMOTO KK (JP) 2003-02-05 CN disclosed
CN-1395551-A Novel arylpropionaldehyde derivatives and production and use of the same AJINOMOTO KK (JP) 2003-02-05 CN disclosed
EP-1249442-A1 NOVEL ARYLPROPIONALDEHYDE DERIVATIVES AND PRODUCTION AND USE OF THE SAME Ajinomoto Co., Inc. (JP) 2002-10-16 EP disclosed
EP-1249442-A1 NOVEL ARYLPROPIONALDEHYDE DERIVATIVES AND PRODUCTION AND USE OF THE SAME Ajinomoto Co., Inc. (JP) 2002-10-16 EP disclosed
WO-2001053243-A1 NOVEL ARYLPROPIONALDEHYDE DERIVATIVES AND PRODUCTION AND USE OF THE SAME AJINOMOTO CO., INC. (JP) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032842-A1 Novel arylpropyl aldehyde derivatives, processes for producing the same, and methods of using the same ALDH7A1, ASPH, DDC ESR1 4324/4885ESR2 4194/4885AR 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.